Results 11 to 20 of about 2,070,589 (168)
Clinical Ophthalmology, 2013 Troels Brynskov,1,2 Caroline Schmidt Laugesen,1 Jakob Halborg,1 Henrik Kemp,1 Torben Lykke Sørensen1,21Department of Ophthalmology, Copenhagen University Hospital Roskilde, Roskilde, Denmark; 2Faculty of Health Sciences, University of Copenhagen ...
Brynskov T +4 more
doaj +8 more sources
Российский офтальмологический журнал, 2018 Purpose: to assess the first results of intravitreal injection of an implant of dexamethasone 0.7mg for the treatment of post-traumatic uveitis and prevention of post-traumatic eyeball subatrophy.
I. E. Ioshin +2 more
doaj +3 more sources
Resolution of Persistent Cystoid Macular Edema due to Central Retinal Vein Occlusion in a Vitrectomized Eye following Intravitreal Implant of Dexamethasone 0.7 mg [PDF]
Case Reports in Ophthalmology, 2012 We report the case of a 62-year-old woman with a history of vitreoretinal surgery for vitreous hemorrhage secondary to central retinal vein occlusion (CRVO).
Michele Reibaldi +8 more
doaj +8 more sources
Dexamethasone 0.7 mg implants in the management of pseudophakic cystoid macular edema
Arquivos Brasileiros de Oftalmologia, 2016 Pseudophakic cystoid macular edema (PCME) is a common complication following cataract surgery. Although majority of patients with PCME remain asymptomatic, it remains an important cause of vision loss after cataract surgery. The pathogenesis of PCME remains unclear, but most authors agree that inflammation plays a major role in its development.
José Maurício Botto de Barros, Garcia +2 more
core +6 more sources
International Medical Case Reports Journal, 2018 P Singh,1 A Chedid,1 SK Deuchler,1 T Kohnen,2 M Müller,2 FH Koch1 1Retina and Vitreous Unit, University Eye Clinic, Frankfurt am Main, Germany; 2Ophthalmology University Eye Hospital, Frankfurt am Main, Germany Purpose: There are little or no ...
Singh P +5 more
doaj +8 more sources
Retrospective, Observational Study in Patients Receiving a Dexamethasone Intravitreal Implant 0.7 mg for Macular Oedema Secondary to Retinal Vein Occlusion [PDF]
Ophthalmologica, 2014 <b><i>Purpose:</i></b> To retrospectively evaluate the re-injection interval, efficacy and safety of dexamethasone (DEX) intravitreal implant 0.7 mg in the treatment of macular oedema (ME) due to retinal vein occlusion (RVO) in Germany in 2009-2012.
Augustin, Albert J. +10 more
core +5 more sources
A New Side Effect of Intravitreal Dexamethasone Implant (Ozurdex®) [PDF]
Case Reports in Ophthalmological Medicine, 2017 Dexamethasone implant, 0,7 mg (Ozurdex, Allergan, Inc., Irvine, CA, USA), is drug mostly used in the treatment of the diabetic macular edema and edema related to retinal vein occlusion.
Erdem Eris +5 more
doaj +2 more sources
Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant
Clinical Ophthalmology, 2010 Jane S Myung, Grant D Aaker, Szilárd KissDepartment of Ophthalmology, Weill Cornell Medical Center, New York, NY, USAPurpose: To report our experience with dexamethasone 0.7 mg sustained-release intravitreal implant (Ozurdex®; Allergan,
Jane S Myung +2 more
doaj +2 more sources
Indian Journal of Ophthalmology, 2012 We report on the significant improvement of central macular thickness in a case of clinically significant macular edema after dexamethasone 0.7 mg sustained-release intravitreal implant (Ozurdex®; Allergan, Inc, Irvine, CA, USA).
Ashish Sharma +4 more
doaj +2 more sources
Intravitreal Dexamethasone Implant (Ozurdex) for Refractory Macular Edema Secondary to Retinitis Pigmentosa [PDF]
Türk Oftalmoloji Dergisi, 2016 Macular edema (ME) in retinitis pigmentosa (RP) often impairs central vision dramatically. A 41-year-old woman diagnosed with RP was referred to our outpatient clinic due to severe visual deterioration in both eyes.
Nurgül Örnek +2 more
doaj +2 more sources